This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2029 Remove Healthcare Provider Remove Side effects
article thumbnail

Managing the next pandemic: the role of nasal vaccine administration

European Pharmaceutical Review

AUGUST 30, 2022

Nasal delivery is non-invasive and provides a more targeted delivery than the systemic injectable approach, potentially offering a quicker response and reduced side effects. million by 2029, up from $122.287 million in 2021. These innovations can go a long way towards making nasal a viable route for vaccine development.

Management 119
Management Manufacturing Marketing Side effects 119
article thumbnail

Digitalisation of the clinical trial landscape

European Pharmaceutical Review

JUNE 16, 2023

According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines.

Safety 111
Safety Electronics Recruitment Patients 111
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
Webinars
About
Editions
Webinars
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024